The costs of acromegaly management in Poland — analysis from one centre
Abstract
Introduction: The analysis of the costs associated with treating acromegaly and its complications is important in planning diagnostics and treatment for a single patient, as well as in establishing the standard of care for the entire population of acromegaly patients. Data on the actual costs of treating patients with acromegaly in Poland are limited.
Aims of the study: To determine the direct cost (hospital stays, diagnostic imaging, surgical treatment, pharmacotherapy, tumour irradiation) of treating patients with acromegaly and its complications, assessing the relationship between acromegaly treatment costs and the radical nature of the treatment.
Materials and methods: A retrospective analysis of medical records was carried out in 124 patients with acromegaly who were hospitalised in the Department of Endocrinology in 2011–2016, including a group of 39 patients who were successfully operated on, 73 patients requiring treatment with a somatostatin analogue, and 12 patients with newly diagnosed disease. The costs of surgical procedures, hospitalisation,
diagnostic tests, and the cost of pharmacological treatment of acromegaly and its complications were analysed and estimated based on the system of homogeneous groups of patients.
Results: The mean total annual cost of acromegaly treatment was PLN 43,419 (EUR 9731). The mean annual cost of treating patients undergoing effective neurosurgical treatment was lower than in the other groups, and the costs of pharmacological and surgical treatment of complications of acromegaly were also lower. The costs of hospitalisation and additional diagnostic tests were highest in patients with newly diagnosed acromegaly.
Conclusions: Treatment with somatostatin analogues is the major cost factor in patients requiring chronic therapy. Effective radical neurosurgical treatment reduces the incidence of chronic complications of acromegaly and lowers the overall treatment costs.
Keywords: acromegalytherapycomplicationscostspharmacoeconomics
References
- Bolanowski M, Ruchała M, Zgliczyński W, et al. Diagnostics and treatment of acromegaly - updated recommendations of the Polish Society of Endocrinology. Endokrynol Pol. 2019; 70(1): 2–18.
- Bolfi F, Neves AF, Boguszewski CL, et al. Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur J Endocrinol. 2018; 179(1): 59–71.
- Giustina A, Barkan A, Beckers A, et al. A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. J Clin Endocrinol Metab. 2020; 105(4).
- Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004; 89(2): 667–674.
- Baris D, Gridley G, Ron E, et al. Acromegaly and Cancer Risk: A Cohort Study in Sweden and Denmark. Cancer Causes and Control. 2002; 13(5): 395–400.
- Mercado M, Gonzalez B, Vargas G, et al. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab. 2014; 99(12): 4438–4446.
- Fleseriu M, Barkan A, Del Pilar Schneider M, et al. Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States. Pituitary. 2022; 25(2): 296–307.
- Whittington MD, Munoz KA, Whalen JD, et al. Economic and clinical burden of comorbidities among patients with acromegaly. Growth Horm IGF Res. 2021; 59: 101389.
- Elbaum M, Mizera Ł, Bolanowski M. The real costs of acromegaly: analysis of different therapies. Endokrynol Pol. 2019; 70(1): 74–85.
- Katznelson L, Laws ER, Melmed S, et al. Endocrine Society. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014; 99(11): 3933–3951.
- Lesén E, Granfeldt D, Houchard A, et al. Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study. Eur J Endocrinol. 2017; 176(2): 203–212.
- Ribeiro-Oliveira A, Brook RA, Munoz KA, et al. Burden of acromegaly in the United States: increased health services utilization, location of care, and costs of care. J Med Econ. 2021; 24(1): 432–439.
- Didoni G, Grottol S, Gasco V, et al. Cost-of-illness study in acromegalic patients in Italy. J Endocrinol Invest. 2004; 27(11): 1034–1039.
- Kamusheva M, Vandeva S, Mitov K, et al. New Epidemiological, Clinical and Economic Data for Patients With Acromegaly in Bulgaria. Front Public Health. 2020; 8: 147.
- Broder M, Neary M, Chang E, et al. Incremental healthcare resource utilization and costs in US patients with Cushing’s disease compared with diabetes mellitus and population controls. Pituitary. 2015; 18(6): 796–802.
- Cocchiara F, Campana C, Nista F, et al. Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length. Pituitary. 2022; 25(2): 246–257.
- Guo X, Wang K, Yu S, et al. Patient Characteristics, Diagnostic Delays, Treatment Patterns, Treatment Outcomes, Comorbidities, and Treatment Costs of Acromegaly in China: A Nationwide Study. Front Endocrinol (Lausanne). 2020; 11: 610519.
- Bolanowski M, Bar-Andziak E, Kos-Kudła B, et al. Consensus of the Polish Society of Endocrinology. Presurgical somatostatin analogs therapy in acromegaly. Endokrynol Pol. 2007; 58(4): 350–353.
- Margusino-Framiñán L, Pertega-Diaz S, Pena-Bello L, et al. Cost-effectiveness analysis of preoperative treatment of acromegaly with somatostatin analogue on surgical outcome. Eur J Intern Med. 2015; 26(9): 736–741.
- Placzek H, Xu Y, Mu Y, et al. Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis. J Manag Care Spec Pharm. 2015; 21(12): 1106–1112.
- Liu S, Adelman DT, Xu Y, et al. Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly. J Investig Med. 2018; 66(3): 653–660.
- Yuen KCJ, Munoz KA, Brook RA, et al. Health Benefit Costs and Absenteeism Among Employed Patients With Acromegaly. Endocr Pract. 2021; 27(10): 1034–1039.
- Rolla M, Jawiarczyk-Przybyłowska A, Halupczok-Żyła J, et al. Complications and Comorbidities of Acromegaly-Retrospective Study in Polish Center. Front Endocrinol (Lausanne). 2021; 12: 642131.
- Elbaum M, Kałużny M, Jawiarczyk-Przybyłowska A, et al. The Relationship between the Burden of Acromegaly, Associated Comorbidities, Complications and Disease Status. J Clin Med. 2023; 12(19).
- Stawerska R, Smalczewska P, Łupińska A, et al. GH-secreting pituitary adenoma in the course of McCune‑Albright syndrome in a 21-year-old patient complicated by hepatocellular carcinoma. Endokrynol Pol. 2023; 74(4): 441–442.
- Gierach M, Junik R. Aberrations in carbohydrate metabolism in patients with diagnosed acromegaly - observational study. Endokrynol Pol. 2022; 73(4): 743–744.
- Duan L, Huang M, Yan H, et al. Cost-effectiveness analysis of two therapeutic schemes in the treatment of acromegaly: a retrospective study of 168 cases. J Endocrinol Invest. 2015; 38(7): 717–723.
- Orlewska E, Kos-Kudla B, Sowinski J, et al. Lanro-Study Group. Dosage and costs of lanreotide Autogel 120 mg administered as part of routine acromegaly care in Poland - two years of data from Lanro-Study. Endokrynol Pol. 2015; 66(2): 142–148.
